Results 211 to 220 of about 21,646 (232)

Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial

Circulation, 2012
Jonas Oldgren, Sean Yang, Michael D Ezekowitz   +2 more
exaly  

Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate

Clinical Pharmacokinetics, 2012
Joachim Stangier, Karin Rathgen, Stangier Joachim   +2 more
exaly  

Decrease in the oral bioavailability of dabigatran etexilate after co‐medication with rifampicin

British Journal of Clinical Pharmacology, 2012
Sebastian Härtter, Ashish Sharma, Gerhard Nehmiz   +2 more
exaly  

Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran Etexilate

Clinical Pharmacokinetics, 2012
Joachim Stangier, Stangier Joachim
exaly  

Dabigatran Compared with Warfarin in Patients with Atrial Fibrillation and Symptomatic Heart Failure: A Subgroup Analysis of the RE-LY Trial

European Journal of Heart Failure, 2013
Michael D Ezekowitz, Mandy Fraessdorf, Paul A Reilly   +2 more
exaly  

Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects

Clinical Pharmacokinetics, 2012
Joachim Stangier, Karin Rathgen, Stangier Joachim   +2 more
exaly  

Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement

Journal of Clinical Pharmacology, 2005
Joachim Stangier, Bengt I Eriksson, Ola E Dahl   +2 more
exaly  

Dabigatran

2016
openaire   +1 more source

Adverse Effects of Dabigatran

Annals of Internal Medicine, 2012
openaire   +2 more sources

Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial

Journal of Thrombosis and Haemostasis, 2011
Thorsten Lehr, S J Connolly, Salim Yusuf   +2 more
exaly